Loading...
•
Dec 31, 2019
Tvardi Therapeutics Q4 2019 Earnings Report
Reported financial results and operational highlights for Q4 and full year 2019.
Key Takeaways
Cara Therapeutics reported a net loss of $28.6 million for the fourth quarter of 2019, compared to a net loss of $20.7 million for the same period in 2018. The company's cash, cash equivalents, and marketable securities totaled $218.2 million at the end of 2019.
Reported positive results from the first pivotal Phase 3 efficacy trial (KALM™ -1) of KORSUVA Injection.
Reported positive results from Phase 2 trial of Oral KORSUVA in pre-dialysis patients.
Expanded clinical pruritus program for Oral KORSUVA with the initiation of Phase 2 trials in both atopic dermatitis and liver disease patients.
Expects top-line data for its pivotal KALM-2 Phase 3 global trial of KORSUVA Injection in the second quarter of 2020.
Forward Guidance
Cara Therapeutics expects its existing cash and cash equivalents and available-for-sale marketable securities as of December 31, 2019 will be sufficient to fund its currently anticipated operating expenses and capital expenditures into the second half of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...